SUMM.L Regulatory News (SUMM)

6 Oct 2006 07:30

VASTox plc06 October 2006 VASTox plc ("VASTox" or "the Company") VASTOX PLC HOSTS R&D DAY TO HIGHLIGHT KEY DEVELOPMENTS Oxford, UK, 6 October 2006 - VASTox plc (AIM: VOX), a leading UK biotechnologycompany, today hosts an R&D day for analysts and investors from 10:45hrs at itsmain site in Milton Science Park, near Oxford. Key members of the senior management team will make presentations aimed atimproving awareness and understanding of the Company, its chemical genomictechnology platforms and therapeutic programmes, in particular its leadprogramme in Duchenne Muscular Dystrophy (DMD). Also, a presentation on the broader issues of the impact of DMD in the communitywill be given by Nick Catlin, CEO of Parent Project UK (PPUK). PPUK is the onlynational charity that exclusively funds research and campaigns for bettermedical care for Duchenne and Becker muscular dystrophy. For details of the presentations given today, please contact VASTox directly atinvestors@vastox.com or Citigate Dewe Rogerson (details below). - ends - For more information please contact: VASTox Steven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443910 Darren Millington, ACMA, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 David Dible / Mark Swallow / Valerie Auffray Mobile: +44 (0)7903 737703 mark.swallow@citigatedr.co.uk About VASTox plc VASTox is a biotechnology company that discovers and develops proprietary noveldrugs and provides services to the pharmaceutical industry. The company's mostadvanced drug development programme is focused on developing a new treatment forDuchenne muscular dystrophy based on the up-regulation of utrophin. A seconddrug development programme for spinal muscular atrophy is also progressingrapidly. VASTox has four additional programmes focused on osteoarthritis,cancer, tuberculosis and stem cell therapies, which are expected to beout-licensed prior to entering the clinic. The company's technology platform, which uses zebrafish and fruitflies, has thepotential to dramatically decrease the time and cost of drug discovery anddevelopment. This is because using whole organisms allows it to carry out highvolume, high content screening, which delivers data that are highly predictiveof the efficacy and toxicity of potential drug compounds in humans. VASTox isgrowing revenues based on marketing its unique technology platform and itschemistry expertise. The company listed on the AIM market of the London StockExchange in October 2004. Further information about the company is available at www.vastox.com This information is provided by RNS The company news service from the London Stock Exchange